ClinicalTrials.gov
ClinicalTrials.gov Menu

Collection of Blood From Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00923221
Recruitment Status : Recruiting
First Posted : June 18, 2009
Last Update Posted : September 26, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

  • It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
  • Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
  • Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.

Objectives:

-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.

Eligibility:

-All patients participating in NCI prostate cancer protocols.

Design:

  • Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
  • Blood samples are collected at the initial visit or at follow-up visits.
  • DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
  • Gene variations are correlated with prostate cancer prognosis and prognostic indicators.

Condition or disease
Prostatic Neoplasms

Detailed Description:

Objectives:

To obtain blood samples from patients with prostate cancer for genotyping analyses.

Eligibility:

All patients seen in the NCI prostate cancer clinic are eligible.

Design:

Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI. Blood samples may be collected at the initial visit or at follow-up visits. Genomic DNA and white blood cells will each be extracted from these samples to be utilized for genotyping and establishment of individual cell lines. Genetic variance will be correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e. histological tumor grade). Healthy controls will not be compared and no correlations will be made with prostate cancer susceptibility.


Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Collection of Blood From Patients With Prostate Cancer
Study Start Date : March 1, 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Group/Cohort
Patient samples
blood samples from patients with diagnosed prostate cancer



Primary Outcome Measures :
  1. Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer to aid in understanding the mechanisms of prostate carcinogenesis and progression [ Time Frame: Study duration ]
    Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer to aid in understanding the mechanisms of prostate carcinogenesis and progression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
male patients with diagnosed prostate cancer
Criteria
  • INCLUSION CRITERIA:

Patients 18 years of age and older are eligible.

Patients with a diagnosis of prostate cancer are eligible.

EXCLUSION CRITERIA:

Children are not eligible.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00923221


Contacts
Contact: William D Figg, Pharm.D. (240) 760-6179 wdfigg@helix.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937      
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: William D Figg, Pharm.D. National Cancer Institute (NCI)

Additional Information:
Publications:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00923221     History of Changes
Obsolete Identifiers: NCT00899249
Other Study ID Numbers: 070100
07-C-0100
First Posted: June 18, 2009    Key Record Dates
Last Update Posted: September 26, 2018
Last Verified: September 24, 2018

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Blood
Prostate Cancer
Genotyping

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases